Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

LAWRENCE E GARBO

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1740276484
CMS profile
350947
Location
ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$15.32

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $15.32 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
E.R. Squibb & Sons, L.L.C. $15.32 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

LAWRENCE E GARBO

NPI 1740276484 · CMS profile ID 350947

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

ALBANY, NY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1740276484?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1740276484?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1740276484?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
LAWRENCE E GARBO, NPI 1740276484, CMS profile ID 350947, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1740276484?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $15.32 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
E.R. Squibb & Sons, L.L.C. $15.3208/13/2020 Education No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 728006985 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $259.57 3
PY2020 $15.32 1
PY2021 $62.51 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021
Source files and profile matching
Source files
Dataset page · Bulk file · PY2019 , PY2020 , PY2021
Generated from
OP_DTL_GNRL_PGYR2021_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $54,555.31 21
PY2024 Principal investigator $121,551.17 52
PY2023 Principal investigator $130,237.17 26
PY2022 Principal investigator $53,938.23 20
PY2021 Principal investigator $175,090.52 37
PY2020 Principal investigator $226,774.25 81
PY2019 Principal investigator $398,858.14 215

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

81 records in PY2020

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,781.00 12/22/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956595
Principal investigator 1 Genentech, Inc. $7,594.00 12/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 743088971
Principal investigator 1 Janssen Research & Development, LLC $81.00 12/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511213
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 12/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740847429
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 12/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740847623
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,734.00 12/01/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956451
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,953.00 10/20/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956729
Principal investigator 1 Genentech, Inc. $4,799.00 10/19/2020 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 743106995
Principal investigator 1 Janssen Research & Development, LLC $709.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511181
Principal investigator 1 Janssen Research & Development, LLC $663.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511183
Principal investigator 1 Janssen Research & Development, LLC $75.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511189
Principal investigator 1 Janssen Research & Development, LLC $75.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511193
Principal investigator 1 Janssen Research & Development, LLC $75.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511197
Principal investigator 1 Janssen Research & Development, LLC $75.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511201
Principal investigator 1 Janssen Research & Development, LLC $198.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511205
Principal investigator 1 Janssen Research & Development, LLC $198.00 10/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719511209
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 10/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740847809
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 10/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740847811
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,781.00 09/22/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956797
Principal investigator 1 Janssen Research & Development, LLC $200.00 09/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509287
Principal investigator 1 Janssen Research & Development, LLC $200.00 09/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509291
Principal investigator 1 Janssen Research & Development, LLC $200.00 09/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509309
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 09/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740847241
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,953.00 08/20/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956473
Principal investigator 1 Janssen Research & Development, LLC $81.00 08/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509305
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 08/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740846861
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 08/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740846863
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 08/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740847045
Principal investigator 1 Genentech, Inc. $4,799.00 08/03/2020 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 743106840
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $253.02 07/29/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 737085847
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,781.00 07/21/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956747
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $506.04 07/16/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 737085201
Principal investigator 1 Janssen Research & Development, LLC $221.00 07/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509296
Principal investigator 1 Janssen Research & Development, LLC $200.00 07/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509301
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 07/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740847239
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $87,404.00 06/24/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 737084041
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,806.00 06/23/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956425
Principal investigator 1 Genentech, Inc. $8,206.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY HUDSON
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 743088961
Principal investigator 1 Janssen Research & Development, LLC $81.00 06/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509991
Principal investigator 1 Janssen Research & Development, LLC $81.00 06/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509995
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740846293
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740846297
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740846299
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740846301
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740846303
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740849119
Principal investigator 1 Seagen Inc. $275.00 06/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY
A Phase 2 Open-label Study of Brentuximab Vedotin in Front-line Therapy of Hodgkin Lymphoma (HL) in Adults Age 60 and Above No dispute reported 06/30/2026 733447927
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $1,125.00 06/11/2020 Non-covered Recipient Entity
Us Oncology Res Llc
An Open Label Phase 2 Multicohort Trial of Nivolumab in Advanced or Metastatic Malignancies (CheckMate 627) No dispute reported 06/30/2026 736764341
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,304.00 05/21/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956699
Principal investigator 1 Janssen Research & Development, LLC $81.00 05/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509977
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509979
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509983
Principal investigator 1 Janssen Research & Development, LLC $200.00 05/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, PC
Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma No dispute reported 06/30/2026 719509987
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $5,174.19 05/08/2020 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Phase III MEL 1L, PD-1 vs Ipi vs. PD-1 Ipi No dispute reported 06/30/2026 736761091
Principal investigator 1 Genentech, Inc. $4,672.00 04/27/2020 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 743106793
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,242.00 04/21/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956679
Principal investigator 1 Eli Lilly and Company $2,868.00 04/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY PC
A PHASE 1B STUDY OF AURORA A KINASE INHIBITOR LY3295668 ERBUMINE IN MONOTHERAPY AND COMBINATION THERAPY IN PATIENTS WITH METASTATIC BREAST CANCER POST CDK4/6 INHIBITOR AND ENDOCRINE THERAPY No dispute reported 06/30/2026 728738883
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 04/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740848553
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 04/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848731
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848931
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 04/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848933
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $3,696.00 03/19/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956705
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $9,487.00 03/17/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956631
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 03/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740846667
Principal investigator 1 Merck Sharp & Dohme Corporation $225.00 03/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740849117
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $180.00 02/19/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 737072425
Principal investigator 1 Genentech, Inc. $5,967.00 01/29/2020 Non-covered Recipient Entity
PHYSICIANS RELIANCE NETWORK US ONCOLOGY RESEARCH INC
TECENTRIQ ONCOLOGY EXTENSION STUDY No dispute reported 06/30/2026 743106611
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $15,487.00 01/28/2020 Non-covered Recipient Entity
Us Oncology Research Llc
An Open-label Single-arm Phase II Study of Regorafenib and Nivolumab in Patients with Mismatch Repair-Proficient (pMMR)/Microsatellite Stable (MSS) Colorectal Cancer (CRC) No dispute reported 06/30/2026 746956651
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,480.00 01/22/2020 Non-covered Recipient Entity
US ONCOLOGY RESEARCH LLC
A RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL OF A+AVD VERSUS ABVD AS FRONTLINE THERAPY IN PATIENTS WITH ADVANCED CLASSICAL HODGKIN LYMPHOMA No dispute reported 06/30/2026 737068247
Principal investigator 1 Celgene Corporation $11,186.00 01/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Celgene - Connect MM No dispute reported 06/30/2026 736445403
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $4,404.00 01/15/2020 Non-covered Recipient Entity
New York Oncology Hematology, Pc
Adaptive Pan Malignancy Study for indications in which there is no approved immunomodulating therapy or BMS registration pathway No dispute reported 06/30/2026 736761101
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740846677
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848547
Principal investigator 1 Merck Sharp & Dohme Corporation $956.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A Randomized, Active-Controlled, Partially Blinded, Biomarker Select, Phase III Clinical Trial of Pembrolizumab as Monotherapy and in Combination with Cisplatin5-Fluorouracil versus PlaceboCisplatin5-Fluorouracil as First-Line Treatment in Subjects with Advanced Gastric or Gastroesophageal Junction GEJ Adenocarcinoma No dispute reported 06/30/2026 740848551
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848733
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848735
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848737
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848739
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848741
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848925
Principal investigator 1 Merck Sharp & Dohme Corporation $105.00 01/15/2020 Non-covered Recipient Entity
NEW YORK ONCOLOGY HEMATOLOGY P.C.
A phase III study of Pomalidomide and Dexamethasone with or without Pembrolizumab in refractory or relapsed and refractory Multiple Myeloma rrMM. No dispute reported 06/30/2026 740848927